Publications

5808 Results

Maintenance BCG immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group study.

Authors
DL Lamm;ED Crawford;B Blumenstein;MF Sarosdy;HB Grossman;RD Bohl;B Lowe;TD Moon;WL Weems;TM Beck;J Montie;JA Smith;J Crissman;CA Coltman Jr
Journal / Conference
ASCO 11:203(#627)
Year
1992
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8507

A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate or high-grade non-Hodgkin's lymphoma: Preliminary results of SWOG-8516 (Intergroup 0067).

Authors
RI Fisher;E Gaynor;S Dahlberg;EM Mize;M Oken
Journal / Conference
ASCO 11:315(#1067), oral, plenary session (Proceedings of ASCO, Vol. 11, March 1992, p.315)
Year
1992
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8516 (INT-0067)

The effect of peri-operative blood transfusion on survival in head and neck cancer.

Authors
DE Schuller;C Scott;K Wilson;R Freer;M Al-Sarraf;J Jacobs;R Ahmad;R Casiano;G Laramore
Journal / Conference
Third International Conference on Head and Neck Cancer 103:(#211)
Year
1992
Research Committee(s)
Head and Neck
Study Number(s)
SWOG-8590 (INT-0034)

Chemotherapy as predictor of compliance.

Authors
JR Jacobs;R Casiano;DE Schuller;TF Pajak;GE Laramore;M Al-Sarraf
Journal / Conference
Third International Conference on Head and Neck Cancer 62:(#49)
Year
1992
Research Committee(s)
Head and Neck
Study Number(s)
SWOG-8590 (INT-0034)

An association between DNA diploid tumors and margin negative surgical resections: Implications for adjuvant trials in patients with advanced, resectable squamous cell carcinomas of the head and neck (SCCHN).

Authors
JF Ensley;H Pietraszkiewicz;M Del Alonso;Z Maciorowski;F deBraud
Journal / Conference
ASCO 11:242(#779)
Year
1992
Research Committee(s)
Head and Neck
Study Number(s)
SWOG-8590 (INT-0034)

The Intergroup study of fluorouracil (5-FU) plus levamisole (LEV) and levamisole alone as adjuvant therapy for stage C colon cancer. A final report.

Authors
C Moertel;T Fleming;J Macdonald;D Haller;J Laurie
Journal / Conference
ASCO 11:161(#457)
Year
1992
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-8591(NCI Intergroup #0035)

A randomized investigation of high-dose (HDAC) versus standard dose (SDAC) cytosine arabinoside with daunorubicin (DNR) in patients with acute myelogenous leukemia.

Authors
J Weick;K Kopecky;FR Appelbaum;D Head;L Elias;L Kingsbury;D Daniels;SP Balcerzak;GM Mills;HE Hynes;CA Coltman Jr;M Grever
Journal / Conference
ASCO 11:261(#856)
Year
1992
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8600

Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistance (MDR) gene expression, is associated with a decreased complete remission (CR) rate and CD34+ patients more frequently achieve CR with high dose cytosine arabinoside.

Authors
CL Willman;KJ Kopecky;J Weick;FR Appelbaum;MR Grever;DR Head;L Elias;SP Balcerzak;GM Mills;HE Hynes
Journal / Conference
ASCO 11:262(#857)
Year
1992
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8600

Biochemical modulation of anthracycline resistance (MDR) in acute leukemia with cyclosporin-A (CSA).

Authors
AF List;C Spier;J Greer;C Azar;J Hutter;S Wolff;S Salmon
Journal / Conference
ASCO 11:264(#866)
Year
1992
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8600

Quantitative PCR analysis of MDR1 mRNA in patients with multiple myeloma.

Authors
BW Futscher;LL Blake;TM Grogan;WS Dalton
Journal / Conference
AACR 33:467(#2792)
Year
1992
Research Committee(s)
Myeloma
Study Number(s)
SWOG-8624